SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-22-218644
Filing Date
2022-08-11
Accepted
2022-08-11 16:52:33
Documents
3
Group Members
ABINGWORTH BIOVENTURES 8 LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d392800dsc13da.htm SC 13D/A 201328
2 EX-99.1 d392800dex991.htm EX-99.1 12916
3 EX-99.4 d392800dex994.htm EX-99.4 11749
  Complete submission text file 0001193125-22-218644.txt   228099
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

IRS No.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice

Mailing Address 18575 JAMBOREE ROAD SUITE 275-S IRVINE CA 92612
Business Address 18575 JAMBOREE ROAD SUITE 275-S IRVINE CA 92612 (858) 283-0280
Reneo Pharmaceuticals, Inc. (Subject) CIK: 0001637715 (see all company filings)

IRS No.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92480 | Film No.: 221156646
SIC: 2834 Pharmaceutical Preparations